MSB 0.43% $1.17 mesoblast limited

Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-140

  1. 15,456 Posts.
    lightbulb Created with Sketch. 5537
    "The science hasn't proved that the treatment works"

    You say science hasn't proved the treatment works; medical evidence from certain cohorts of the recent phase 3 double blinded RCT's say different - I hate to be the bearer of bad news but as an MD you should know that a RCT is in fact a medical scientific experiment (science) ... so the science proved that in certain cohorts the treatment did actually work !

    Sure the trials missed the PE's and this will hinder the regulatory approval process but to say that the treatments didn't work at all is blatantly false .....

    .... but hey we should take the words of an anonymous poster on a stock forum who says "it just doesn't work cart blanche" simply because it missed the PE over and above medical Professionals and Statisticians who have actually seen the data first hand - yeah right

    Enjoy your day
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.17
Change
0.005(0.43%)
Mkt cap ! $1.358B
Open High Low Value Volume
$1.15 $1.20 $1.15 $1.713M 1.462M

Buyers (Bids)

No. Vol. Price($)
40 60130 $1.17
 

Sellers (Offers)

Price($) Vol. No.
$1.18 25546 7
View Market Depth
Last trade - 11.53am 16/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.